Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. - Wikidata - awgldk - TriplyDB

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

http://www.wikidata.org/entity/Q36941951

about

Efficacy of Transcranial Magnetic Stimulation (TMS) in the Treatment of Schizophrenia: A Review of the Literature to Date Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems Translating the MAM model of psychosis to humans Towards medication-enhancement of cognitive interventions in schizophrenia Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis Epigenetic reprogramming of cortical neurons through alteration of dopaminergic circuits.The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors.Are we studying and treating schizophrenia correctly?Using computational patients to evaluate illness mechanisms in schizophrenia.The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment Theranostic Biomarkers for Schizophrenia The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum.Disruption of Akt signaling decreases dopamine sensitivity in modulation of inhibitory synaptic transmission in rat prefrontal cortex.Positron emission tomography molecular imaging for drug development.Schizophrenia: an integrated sociodevelopmental-cognitive model.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.PharmGKB summary: dopamine receptor D2 Impact of antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia.Comparison of cerebral blood flow in oral somatic delusion in patients with and without a history of depression: a comparative case series The promise of biological markers for treatment response in first-episode psychosis: a systematic review.Prolactin-a biomarker for antipsychotic treatment response?Translating glutamate: from pathophysiology to treatment.Dopamine's Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study.From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.Glutamate and dopamine in schizophrenia: an update for the 21st century Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people.The nature of dopamine dysfunction in schizophrenia and what this means for treatment.Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis.Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study Molecular imaging as a guide for the treatment of central nervous system disorders Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study.

P2860

Q26782386-397A6301-9DD0-4C77-B8F8-D226412EF234 Q26786247-63ABB10B-7793-4CB4-AF99-CEFEF58B3BF3 Q26860217-58FAD07F-1C84-433D-BB35-2069903D02EB Q26860777-AFB425E7-3AC9-492E-8944-513D933E8EDE Q27026382-BEDC2ACA-50A4-48E2-B68E-6711CACB30C5 Q28087255-BBB7C063-4891-4805-AA34-A534B2939660 Q30413207-053AEEFB-ACB5-4362-AEA8-65427C7C325D Q30437188-087B55C9-E907-488C-82DA-C5A7FF247AC8 Q30453020-3EC4080C-D0F9-46E5-ABDD-D83CF037ABBC Q30465313-BDE30216-7B3F-43C1-BDDD-C86AD4C66DD4 Q30500752-5E0F2133-6725-487B-8D37-9F314C0F0A3C Q33593061-E5A8C453-1FC1-419E-86CF-6754D24C6056 Q33624412-D6B8A16C-FF29-4910-A4AD-EF6FAF3B1EA1 Q33635632-54DC2C47-1E41-41A9-8FA9-91E092E7A2C7 Q33893744-A7D10EFA-97DB-4032-966C-E1C9488B74DA Q33991881-85B773E6-D96E-4CE7-AC52-D12F0D3AC56F Q34023115-4FF5603E-CC3A-463A-8382-ED56BAF24C10 Q34131354-9115E31C-A16A-4638-BD29-B5F3644AFADF Q34140126-C1B0C50F-9E31-4A1B-A3C8-1CCA2CDF8C3A Q34970259-8CDF4332-3087-4F31-B70A-2B8A34E548A1 Q35096515-EB09E0CA-6E76-41F2-9529-57F4985F8CE5 Q35190797-258B897F-CD11-4E70-B38C-53FEDAA61288 Q35369988-DFE0DE04-0CBD-4564-9D19-BBEF748D5D60 Q35559926-CEE643FF-A924-48F4-8B86-CFD8CB3617F4 Q35739457-9D491419-8E75-446C-BEDD-775DF1E16D90 Q35795738-05B69985-436C-4549-9908-37C1BC8DC6FE Q35866868-22F40FC7-55CA-4A6E-B3B9-EB0814D89C9A Q36621010-D0F9DA3D-7C36-4CFF-9137-CA528DB15A4B Q36817154-AF751850-BF86-4B11-874B-42CBC7169DD7 Q36871782-8075ECD3-D4A6-4D88-9302-58E6A39AA9B0 Q36872150-B8E90413-63DA-43C6-96A7-2750697B8FD8 Q36928703-215901E6-9B69-47F1-8AEC-9970FBBD4D79 Q36939999-90A13580-82A1-4B56-BDC4-60414DFFB8EB Q36992322-C856A83A-47A9-4590-84DF-B05E3DC6A652 Q36994341-BB8ADC76-8CC6-48D8-8F7D-C0B4C6C2DD7C Q37062793-1098DDE2-F7E9-4E06-ACB5-AF414926CF70 Q37228333-BCED8A8D-89FB-421D-A9EA-CC44B6B5F62B Q37256211-A0DEEC15-D974-4F5E-AD77-D3F49BADF38F Q37262953-C8034123-A72C-491E-9817-23E0AB8360F6 Q37307572-7DAEB3D2-3906-4A8F-8C61-EFE661F46B72

P2860

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

http://www.wikidata.org/entity/Q36941951

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Mechanisms underlying psychosi ...... ts from PET and SPECT imaging.

@en

type

label

Mechanisms underlying psychosi ...... ts from PET and SPECT imaging.

@en

prefLabel

Mechanisms underlying psychosi ...... ts from PET and SPECT imaging.

@en

P1433

Q36941951-B0D1202D-0BEF-417C-9CE2-0615AC85AFBF

P1476

Q36941951-A233A4B8-3BA1-4D7F-A05B-75F205A27B7C

P2093

Q36941951-17B8E60F-626D-4D5B-898C-E3575E16D6F3

Q36941951-E8CDD3C8-5AE5-47F6-A848-5B801744CCFD

P2860

Q36941951-07298047-B474-4E86-86D6-FABB03B259B5

Q36941951-074156E2-5394-4BE0-A039-3D49DD9C28ED

Q36941951-0990584C-33E9-413B-BE11-4FC0AC1C6D25

Q36941951-0EADE11D-1132-49B4-AEA1-2627887F0E61

Q36941951-10275F2C-9A1E-4B96-AB27-0410BD34F6FD

Q36941951-143ED9DE-76AE-4807-BBE6-5B458DAEC990

Q36941951-1521A092-1F03-4914-8FEC-D84C106230A5

Q36941951-16026637-3022-4F6E-B5CA-9882D4010CFE

Q36941951-1764A022-DE34-44BE-95FB-D78D880784EF

Q36941951-17FC8836-B81D-4C8A-831B-DC8F396957FB

P304

Q36941951-69F7FF07-B911-4B0A-BE13-410D619A63BF

P31

Q36941951-7A8A63C1-79C9-484C-AE86-F8D043C728AA

P356

Q36941951-0F321E18-F2CD-4BC4-99F0-AC830F51AE73

P433

Q36941951-B344B172-63F5-4944-B64F-60EE7DDD8802

P478

Q36941951-ABF98084-1A13-475E-B125-790FAC2AD574

P50

Q36941951-38C227F6-C837-4732-BFCD-1BEC963DE9A7

Q36941951-4590349F-C398-4DAA-AA14-92B68B6ED441

Q36941951-676D3282-5896-4FE3-B8F8-87E5A494E5C0

Q36941951-C6FF3C5C-080F-46BB-B13F-25A56E449B2F

P577

Q36941951-6B33A761-423E-4A88-8DFF-CDFCC7B67052

P698

Q36941951-21998BC4-4B89-494F-AA47-B2F5D18FA37F

P921

Q36941951-3C1DD822-FD8A-4F7B-A1FD-D569FF7E3AF7

P932

Q36941951-CC83C20E-B3F6-4FC3-80AE-9F679A69C0CC

P356

138161209788957528

P1433

Current Pharmaceutical Design

P1476

Mechanisms underlying psychosi ...... hts from PET and SPECT imaging

@en

P2093

A Egerton

http://www.w3.org/2001/XMLSchema#string

V Allan

http://www.w3.org/2001/XMLSchema#string

P2860

A systematic review of the prevalence of schizophrenia.

The dopamine hypothesis of schizophrenia: version III--the final common pathway

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

Schizophrenia: manifestations, incidence and course in different cultures A World Health Organization Ten-Country Study

What causes the onset of psychosis?

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

Functional neuroimaging in schizophrenia: diagnosis and drug discovery.

P304

2550-2559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/138161209788957528

http://www.w3.org/2001/XMLSchema#string

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19689327

http://www.w3.org/2001/XMLSchema#string

P921

P932

3687204

http://www.w3.org/2001/XMLSchema#string